Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Paces Ferry Wealth Advisors LLC

Paces Ferry Wealth Advisors LLC reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 495 shares of the biopharmaceutical company’s stock after selling 19 shares during the quarter. Paces Ferry Wealth Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $520,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Vanguard Personalized Indexing Management LLC boosted its position in Regeneron Pharmaceuticals by 13.4% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 9,559 shares of the biopharmaceutical company’s stock worth $10,047,000 after purchasing an additional 1,129 shares during the period. Meiji Yasuda Asset Management Co Ltd. lifted its stake in shares of Regeneron Pharmaceuticals by 5.4% during the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,314 shares of the biopharmaceutical company’s stock worth $2,432,000 after purchasing an additional 119 shares in the last quarter. Argent Trust Co boosted its position in shares of Regeneron Pharmaceuticals by 1.3% in the second quarter. Argent Trust Co now owns 2,370 shares of the biopharmaceutical company’s stock worth $2,491,000 after buying an additional 31 shares during the period. Mercer Global Advisors Inc. ADV boosted its position in shares of Regeneron Pharmaceuticals by 4.8% in the second quarter. Mercer Global Advisors Inc. ADV now owns 24,319 shares of the biopharmaceutical company’s stock worth $25,479,000 after buying an additional 1,122 shares during the period. Finally, E Fund Management Co. Ltd. grew its stake in shares of Regeneron Pharmaceuticals by 38.2% in the second quarter. E Fund Management Co. Ltd. now owns 2,339 shares of the biopharmaceutical company’s stock valued at $2,458,000 after buying an additional 646 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the topic of several recent research reports. Truist Financial reissued a “buy” rating and set a $1,200.00 price target (up from $1,135.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 2nd. JPMorgan Chase & Co. upped their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $1,282.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday. Morgan Stanley cut their price objective on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Finally, Argus raised their target price on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a research note on Tuesday, June 25th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $1,111.30.

Regeneron Pharmaceuticals Stock Down 0.7 %

REGN stock opened at $1,138.81 on Thursday. The firm has a market cap of $125.48 billion, a price-to-earnings ratio of 33.64, a PEG ratio of 3.97 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a 1-year low of $769.19 and a 1-year high of $1,211.20. The firm has a fifty day moving average price of $1,129.45 and a two-hundred day moving average price of $1,029.70. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. During the same quarter in the prior year, the firm earned $8.79 EPS. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, EVP Joseph J. Larosa sold 1,866 shares of the stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the completion of the transaction, the executive vice president now directly owns 37,937 shares of the company’s stock, valued at approximately $41,311,496.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The disclosure for this sale can be found here. Insiders sold a total of 10,026 shares of company stock worth $11,498,705 in the last three months. 7.48% of the stock is owned by insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.